Evolution of polypharmacy in a spanish population (2005-2015): A database study.

Miguel Ángel Hernández-RodríguezErmengol Sempere-VerdúCaterina Vicens-CaldenteyFrancisca Gonzalez-RubioFélix Miguel-GarcíaVicente Palop-LarreaRamón Orueta-SánchezÓscar Esteban-JiménezMara Sempere-ManuelMaría Pilar Arroyo-AniésBuenaventura Fernández-San José

Published in: Pharmacoepidemiology and drug safety (2020)

The prevalence of polypharmacy in this Spanish population has tripled in the period 2005-2015, while excessive polypharmacy has increased 10-fold. These increments are seen in both sexes and in all age groups, particularly in individuals over 80 years of age. The proportion of patients without chronic treatments has decreased.

Keyphrases

end stage renal disease
adverse drug
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
physical activity
weight gain